Seagen Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

12 equities research analysts have issued 1 year price objectives for Seagen's shares. Their SGEN stock forecasts range from $132.00 to $220.00. On average, they expect Seagen's stock price to reach $169.15 in the next year. This suggests that the stock has a possible downside of 5.5%.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

Seagen's stock was trading at $154.60 at the start of the year. Since then, SGEN shares have increased by 15.8% and is now trading at $179.06.
View the best growth stocks for 2022 here.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Seagen.

Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings data on Thursday, April, 28th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.24. The biotechnology company earned $426.50 million during the quarter, compared to the consensus estimate of $401.75 million. Seagen had a negative trailing twelve-month return on equity of 21.86% and a negative net margin of 41.32%. Seagen's quarterly revenue was up 28.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.67) earnings per share.
View Seagen's earnings history.

Seagen updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.67 billion-$1.75 billion, compared to the consensus revenue estimate of $1.78 billion.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (8.40%), BlackRock Inc. (7.44%), Wellington Management Group LLP (6.78%), Vanguard Group Inc. (6.67%), Primecap Management Co. CA (2.51%) and State Street Corp (1.92%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Bank of America Corp DE, Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., UBS Group AG, First Trust Advisors LP, and Tobam. Company insiders that have sold Seagen company stock in the last two years include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Woodline Partners LP, BlackRock Inc., Capital Group Private Client Services Inc., Eagle Health Investments LP, Artal Group S.A., and Vanguard Group Inc..
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $179.06.

Seagen (NASDAQ:SGEN) has a market capitalization of $32.96 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674.47 million in net income (profit) each year or ($3.770010) on an earnings per share basis.

Seagen employs 2,675 workers across the globe.

Seagen was founded in 1998.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for Seagen is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.